Literature DB >> 23997460

Next generation therapy in chronic myeloid leukemia.

Pranab Kumar Bhattacharya1, Upasana Bhattacharya, Rupak Bhattacharya, Ritwik Bhattacharya, Soumyak Bhattacharya, Rupsa Bhattacharya, Dalia Mukherjee, Oindrila Mukherjee, Debasis Mukherjee, Debasis Roy Barman, Soma Das, Anuradha Dey, Ranu Roy Biswas, Surajit Sarkar.   

Abstract

Entities:  

Year:  2012        PMID： 23997460      PMCID： PMC3422381          DOI： 10.1007/s12288-011-0139-2

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.900


× No keyword cloud information.
  4 in total

1.  Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia.

Authors:  L Roy; J Guilhot; G Martineau; R Larchée; F Guilhot
Journal:  Leukemia       Date:  2005-09       Impact factor: 11.528

2.  Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.

Authors:  Dushyant Verma; Hagop Kantarjian; Sara S Strom; Mary Beth Rios; Elias Jabbour; Alfonso Quintas-Cardama; Srdan Verstovsek; Farhad Ravandi; Susan O'Brien; Jorge Cortes
Journal:  Blood       Date:  2011-08-16       Impact factor: 22.113

3.  Severe peripheral arterial disease during nilotinib therapy.

Authors:  Philipp Le Coutre; Delphine Rea; Elisabetta Abruzzese; Hervé Dombret; Malgorzata M Trawinska; Susanne Herndlhofer; Bernd Dörken; Peter Valent
Journal:  J Natl Cancer Inst       Date:  2011-08-02       Impact factor: 13.506

4.  Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.

Authors:  Karl J Aichberger; Susanne Herndlhofer; Gerit-Holger Schernthaner; Martin Schillinger; Gerlinde Mitterbauer-Hohendanner; Christian Sillaber; Peter Valent
Journal:  Am J Hematol       Date:  2011-04-27       Impact factor: 10.047
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.